SearchDictionaryMobileLogin

Lobular Carcinoma

Subscribe to Selected New Research on Lobular Carcinoma
428  relevant articles (5 outcomes, 34 trials/studies) found for this Disease

Description: A infiltrating (invasive) breast cancer, relatively uncommon, accounting for only 5%-10% of breast tumors in most series. It is often an area of ill-defined thickening in the breast, in contrast to the dominant lump characteristic of ductal carcinoma. It is typically composed of small cells in a linear arrangement with a tendency to grow around ducts and lobules. There is likelihood of axillary nodal involvement with metastasis to meningeal and serosal surfaces. (DeVita Jr et al., Cancer: Principles & Practice of Oncology, 3d ed, p1205)

Also Known As:
Carcinoma, Lobular; Carcinomas, Lobular; Lobular Carcinomas

Relationship Network

Disease Context: Research Results

-
Neoplasms: 415397
-
Neoplasms by Histologic Type: 1
-
Glandular and Epithelial Neoplasms: 252
-
Carcinoma: 92356
-
Adenocarcinoma: 27452
*
Lobular Carcinoma: 428
-
Neoplasms, Ductal, Lobular, and Medullary
*
Lobular Carcinoma: 428

Related Diseases

1. Noninfiltrating Intraductal Carcinoma (DCIS)
2. Breast Neoplasms (Breast Cancer)
3. Hyperplasia
4. Adenocarcinoma
5. Meningeal Carcinomatosis

Experts

1. Katz, Artur: 2 articles (01/2007 - 09/2005)
2. Hortobagyi, Gabriel N: 2 articles (12/2006 - 01/2005)
3. Kau, Shu-Wan: 2 articles (12/2006 - 01/2005)
4. Cristofanilli, Massimo: 2 articles (12/2006 - 01/2005)
5. Pinto, Marguerite M: 1 article (10/2008)
6. Choi, Young J: 1 article (10/2008)
7. Riba, Ali K: 1 article (10/2008)
8. M Pinto, Marguerite: 1 article (10/2008)
9. Hao, Liming: 1 article (10/2008)
10. K Riba, Ali: 1 article (10/2008)

Drugs and Biologics

Drugs and Important Biological Agents (IBA) related to Lobular Carcinoma:
1. Cadherins (E-Cadherin)IBA
2. TamoxifenFDA LinkGeneric
10/01/1995 - "The cytological diagnosis of lobular carcinoma permits a discriminating therapeutic approach with pre-operative Tamoxifen, more generous resection margins, and assessment of the contralateral breast. "
09/01/2006 - "The statistically significant risk factors included menopause (Hazard Ratio (HR) =1.56, (1.00-2.42)), invasive lobular carcinoma (HR=2.98, (1.35-6.56)), receiving chemotherapy (HR=2.21, (1.43-3.42)) and/or radiotherapy (HR=3.32, (2.19-5.05) and a protective factor was tamoxifen therapy (HR=0.5 (0.34-0.74). "
12/01/2001 - "The Breast Cancer Prevention Trial (P-1: BCPT) of the National Surgical Adjuvant Breast and Bowel Project (NSABP) randomized 13,388 women, > or = 35 years of age, at increased risk for breast cancer [> or = 1.66% by Gail model criteria or with a history of lobular carcinoma in situ (LCIS)] to 5 years of tamoxifen or placebo. "
01/01/2008 - "CASE REPORT: A 54-year-old perimenopausal woman on tamoxifen (20 mg/day), gravida 0, with surgically treated invasive lobular breast cancer and extensive lobular carcinoma in situ (pT2 (m) pN0 (snl) pL0 G2 pTis (LCLIS) R0 M0 Ki-67 1%, ER+, PR+, Her-2-neu-negative) was referred for evaluation of a pelvic mass. "
11/01/2005 - "RESULTS: Oestrogen receptor positive ductal carcinomas responded as expected to tamoxifen, whereas the difference in recurrence free survival between control and tamoxifen treated patients was less apparent in the relatively few lobular carcinomas. "
Order ALL the reference details at left...
3. Progesterone Receptors (Progesterone Receptor)IBA
4. CateninsIBA
5. docetaxel (Taxotere)FDA Link
6. Cytarabine (Cytosar-U)FDA LinkGeneric
7. Keratins (Keratin)IBA
8. ParaffinIBA
9. AntibodiesIBA
10. Biological Markers (Surrogate Marker)IBA

Therapies and Procedures

1. Segmental Mastectomy (Lumpectomy)
2. Mastectomy (Mammectomy)
3. Drug Therapy (Chemotherapy)
4. Lymph Node Excision (Lymph Node Dissection)
5. Radical Mastectomy

Best Treatments:
Research Summary Report
on Lobular Carcinoma
*WARNING* This specific disease subtype has a relatively small number of significant evidence outcomes. You may proceed to order anyway, or go back to the search field and enter a more general type of the target illness. Once your report has been ordered, however, we can't refund the purchase.

CureHunter Patient-Physician Summary Reports collect in one document all the medications ever reported in the US National Library of Medicine—1949 to the present—to be effective against your target disease. CureHunter research summary reports will vary in length from 25 to 250 pages. Analytic charts allow you and your physicians to see at a glance your medication options—including new, promising, off-label and experimental all rated for clinical efficacy.
  • Free Updates for 1 Year
  • All 5 Outcomes
  • Top 200 Key Drugs and Biologics
  • Top 20 Key Therapies and Procedures
  • Detailed History Charts
  • Full Research Reference Details
  • Sample PDF Report on Psoriasis >>
Price:$24.00 & Delivery via PDF download
updates for 1 year
Research Interface

 

Rapidly retrieve summaries of all the evidence for any disease in seconds. Save hours of search and analysis time. CureHunter is unlike any "search engine" you have ever used. Where standard "search engines" produce lists of links, CureHunter quantifies evidence, extracts it from the literature and calculates a result you can use to immediately facilitate evidence based decision making in Real Clinical Time.
  • Unlimited Disease, Drug and Therapy Search
  • 2 clicks from Disease to Drug to Evidence
  • Trial References
  • All the Positive Outcomes
  • Detailed Relationship Timeline Charts
  • Full Article Reference Details
  • Includes Mobile Interface Subscription
  • One-click to FDA Products/Patents
  • Request Institution License Details >>
Price:$490.00 access via web interface
1 year subscription
Proceed to Checkout >>
Mobile Interface

Retrieve summaries of all the evidence for any disease from your Mobile Phone or PDA. Accelerate decision making in the field. Speed up your study of new drug and disease domains. Refresh your knowledge on the road.
  • Access from any web enabled PDA or Phone
  • Trial references
  • All the Positive Outcomes
  • Drug and Therapy searches
  • Full Article Reference Details
  • Try Mobile Interface >>
Price:$45.00 access via "curehunter.com/m"
1 year subscription
Proceed to Checkout >>